PT - JOURNAL ARTICLE ED - , TI - New fluoroquinolone antibiotics AID - 10.1136/dtb.1999.3716 DP - 1999 Jan 01 TA - Drug and Therapeutics Bulletin PG - 6--8 VI - 37 IP - 1 4099 - http://dtb.bmj.com/content/37/1/6.short 4100 - http://dtb.bmj.com/content/37/1/6.full SO - Drug Ther Bull1999 Jan 01; 37 AB - Relevant BNF section: 5.1.12In 1993, we reviewed three fluoroquinolone antibiotics (ciprofloxacin, norfloxacin and ofloxacin).1 Since then, four more fluoroquinolones have been awarded marketing authorisations. Here we review the clinical evidence and discuss the place of two of these drugs, â–¼grepafloxacin (Raxar - GlaxoWellcome) and â–¼levofloxacin (Tavanic - Hoechst Marion Roussel). Sparfloxacin and trovafloxacin are not considered, as they are not yet commercially available.